Edition:
India

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

104.53USD
16 Feb 2018
Change (% chg)

$1.44 (+1.40%)
Prev Close
$103.09
Open
$102.70
Day's High
$104.79
Day's Low
$102.70
Volume
279,823
Avg. Vol
334,225
52-wk High
$112.83
52-wk Low
$90.21

Select another date:

Thu, Feb 1 2018

BRIEF-Quest Diagnostics Reports Q4 Adjusted Earnings Per Share $1.40

* QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER

BRIEF-Fresenius Medical Care Closes Divestment Of Shiel Medical Laboratory To Quest Diagnostics

* DGAP-NEWS: FRESENIUS MEDICAL CARE CLOSES DIVESTMENT OF SHIEL MEDICAL LABORATORY TO QUEST DIAGNOSTICS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Quest Diagnostics provides update on impact of 2018 Medicare payment rates

* Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests

BRIEF-FDA approves Clinical Genomics, Quest Diagnostics Insure One

* Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™

BRIEF-Quest Diagnostics acquires certain assets of California Laboratory Associates

* Quest Diagnostics acquires California Laboratory Associates

BRIEF-Advantage Capital Portfolio company Cleveland Heartlab acquired by Quest Diagnostics

* Advantage Capital Portfolio company Cleveland Heartlab, Inc acquired by Quest Diagnostics

BRIEF-Quest Diagnostics reports Q3 diluted eps of $1.15

* Quest Diagnostics reports third quarter 2017 financial results, updates 2017 financial guidance and reaffirms long term outlook

BRIEF-Fresenius Medical Care says divests Shiel Medical Laboratory to Quest Diagnostics

* Deal to generate modest book gain for Fresenius Medical Care

BRIEF-Quest Diagnostics provides update on impact to 3rd quarter financial results from hurricanes

* Quest Diagnostics provides update on impact to third quarter financial results from hurricanes

Fitch Affirms Quest Diagnostics at 'BBB'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, September 27 (Fitch) Fitch Ratings has affirmed the ratings of Quest Diagnostics Incorporated (NYSE: DGX) including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings can be found at the end of the release. KEY RATING DRIVERS Leading Market Position: Quest is the largest independent player as measured by segment revenues in the relatively fragmented and highly competitive U.S. clinic

Select another date: